Salzburg, Austria-based medPhoton GmbH announced that its new cone-beam CT (CBCT) imaging system, ImagingRing, has gained FDA approval.
The integrated solution, which offers both 2D and 3D imaging, is now available in the United States to users of Mevion Medical Systems’ MEVION S250 proton therapy systems. It included a 102-cm bore with ceiling rail mounting.
“We are excited to receive FDA clearance for the ImagingRing,” Heinz Deutschmann, CEO and founder of medPhoton, said in a prepared statement. “We look forward to expanding the collaboration with Mevion and continuing the development of new capabilities and features to enhance the imaging tools and isocentric workflow for Mevion systems, including ultra large field of view scans, dual energy options and 4D motion management.”
“We congratulate medPhoton on the 510(k) clearance of the ImagingRing,” Tina Yu, CEO of Mevion Medical Systems, said in the same statement. “The addition of the ImagingRing has been integral to our commitment to provide state-of-the-art proton therapy solutions to our customers.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.